Last reviewed · How we verify
Artemether-Lumefantrine: P. vivax
At a glance
| Generic name | Artemether-Lumefantrine: P. vivax |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety of Antimalarials in the FIRst trimEster (PHASE3)
- Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield (NA)
- ACT vs CQ With Tafenoquine for P. Vivax Mono-infection (PHASE4)
- Short Course Radical Cure of P. Vivax Malaria in Nepal (PHASE4)
- A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh (PHASE4)
- Blood-Stage Plasmodium Vivax Cell Bank (PHASE1)
- Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa... (PHASE1, PHASE2)
- Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: